abbvie glp-1 receptor agonist medications How Agonists Evolved from Diabetes to Weight Loss Treatments The Use of GLP-1 Agonists

This rationing impacted the electronics sector but also had a cascading effect on other industries reliant on microchips, like automotive and home appliances

Obesity Landscape - Final Thoughts Dosing The GLP-1 RA obesity market, driven by injectables, has seen historic levels of success, and near-term entrants are likely to provide more dosing options within the GLP-1 or GLP-1/GIP class Weight Loss Novel drugs in development are likely to be approved within the next 5 years, with improved weight loss efficacy compared to what Wegovy and Zepbound have demonstrated Body Comp The coming years will likely see increased data on muscle preservation and the quality of weight loss with novel MoAs, even if used in combination with GLP-1/incretin-targeting agents As the obesity market matures, how will patients think about the tradeoffs between efficacy, safety, and dosing/convenience with the availability of new drugs and more data

Amp-activated protein kinase plays a role in the control of food intake

doi: 10.1111/cen.14583 24 Becker-KrailDDWalkerWHNelsonRJ

Some research suggests that fiber-rich foods and gut microbiome activity may influence GLP-1 signaling

Heres commentary from Lily management: There's no doubt in my mind, Geoff in five years, as I said, we're going to have a lot more data and we're going to see these drugs as foundational medical treatment for many chronic diseases, and with outcomes to hard outcomes data that moves the cost curve in populations. And eventually the Venn diagram of seniors who have obesity or overweight and other conditions, diabetes, of course already we have access in many plans there, but we'll be adding to that pie